SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix (NFLX) is trending after its latest earnings report, revealing strong ad-tier growth and expanding margins, yet the stock saw a notable decline following cautious forward guidance and the cessation of share buybacks. The community is sharply divided, with many seeing this as a prime long-term buying opportunity, while others anticipate further downside, citing the potential Warner Bros. Discovery acquisition's impact on debt and shareholder value. This pivotal moment highlights a tug-of-war between Netflix's core business strength and strategic M&A concerns.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold is surging to new all-time highs, propelled by escalating geopolitical tensions stemming from recent tariff threats against European nations and discussions around Greenland. The community views this as a significant risk-off catalyst, driving substantial safe-haven inflows amid broader concerns over global stability and the dollar's future. While many anticipate further gains, calls for caution and potential profit-taking are also emerging as the metal's ascent becomes parabolic.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to multiple analyst upgrades and recent news of a significant U.S. SHIELD defense contract for chip supply, which the community views as a major catalyst. Investors are actively discussing the upcoming earnings, robust demand for server CPUs driven by AI, and the stock's notable resilience amidst broader market volatility, with many anticipating a move past key resistance levels.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to reports of a potential acquisition by Zydus Lifesciences, sparking community speculation about a bidding war for the undervalued biotech. This is amplified by recent strong preliminary financial results, accelerated IBSRELA revenue guidance to $1 billion by 2029, and a pivotal patent extension to 2041 for both its key therapies. These developments firmly position Ardelyx as a compelling long-duration asset and an attractive target in the current biotech market landscape.

America's Oil Reserve for the Digital Age

U.S Oil

USOR Crypto is trending amidst extreme volatility, with community members fiercely debating its legitimacy as a Solana meme coin following a rapid price surge. While some anticipate significant further gains leading up to a key February 1st date, others are cautioning against a potential "rug pull" scenario, with many also discussing its inconsistent availability on various exchanges.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is currently trending following news of a significant public offering and a strategic private placement to Medtronic, exciting investors about potential validation and future prospects. The community is actively discussing the implications of this institutional investment and the concurrent start of its pivotal PARADIGM trial for the DurAVR heart valve, balancing optimism with concerns over share dilution.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid significant market uncertainty, driven by recent geopolitical rhetoric concerning Greenland and potential tariffs. While some investors anticipate a quick V-shaped rebound, others are bracing for further downside, with rising gold prices reflecting broader market anxiety. The community is actively debating whether these developments are temporary "noise" or signal a more substantial correction, especially considering underlying bond market concerns.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending amidst significant market uncertainty driven by former President Trump's recent geopolitical rhetoric concerning Greenland and tariffs, coupled with anticipation of his upcoming Davos speech. This has spurred intense community debate, with some advocating to "buy the dip" while others voice concerns over a potential market downturn, especially as gold prices reach new all-time highs.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is trending due to significantly raised revenue guidance for 2026 and its strategic expansion into the space domain with a new contract win. The community is actively discussing the company's potential as a defense, AI, and robotics player, with many anticipating future government contracts and a possible short squeeze, despite some past volatility.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following its licensing deal with Pfizer for the Matrix-M adjuvant, a move seen by many as a significant validation of its platform and a potential precursor to further partnerships. The community remains highly engaged, debating the stock's high short interest and the impact of existing convertible bonds on price, alongside ongoing calls for decisive management action to unlock shareholder value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood, Founder & CEO, Ark Invest, speaks during the second day of the FII PRIORITY Summit

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.

Equity

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.


A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena. (Photo by Sarah Reingewirtz/MediaNews Group/Los Angeles Daily News via Getty Images)

Nano-Cap Regentis Biomaterials Stock Is Up Nearly 15% This Year: Why Retail Traders Are Swarming It

Heading to close this week as its best week since IPO, RGNT has become a retail favorite with surging followers on Stocktwits.

MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab

The FDA said that the drug, which treats a chronic inflammatory skin disorder, could establish evidence without additional trials.

Currency and Exchange Stock Chart for Finance and Economy Display. (Image Courtesy: Getty Images)

TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally

Strong 2026 guidance and accelerating uptake of its MS drug send TGTX to its best session in months, with Wall Street and retail piling in.

<ul class="summary-bullets"><li>The company sees 2025 revenue of $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.</li><li>BRIUMVI’s U.S. net product revenue expected to reach around $182 million in Q4 and $594 million in 2025.&nbsp;</li><li>TG Therapeutics stock rallies 9% higher in Wednesday’s premarket.&nbsp;</li></ul><p>TG Therapeutics, Inc. (TGTX) drew increased attention on Wednesday, with the stock seeing a 195% increase in retail chatter on Stocktwits over the last 24 hours following the company’s ambitious revenue outlook.&nbsp;</p><p>On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.</p><h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><p><a href="https://stocktwits.com/symbol/TGTX">TG Therapeutics stock</a> traded over 9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_083034_png_390ef2e760.webp" alt="TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits" width="933" height="108"><figcaption>TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits</figcaption></figure><p>A Stocktwits user sounded optimistic about BRIUMVI achieving blockbuster status.</p><p><stembedurl>https://stocktwits.com/knowthyself/message/641747123</stembedurl></p><p>Another bullish user said the company’s ramp-up from Q3 to Q4 was impressive.&nbsp;</p><p><stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/641752748</stembedurl></p><h2 class="st-heading-2">Outlook Highlights&nbsp;</h2><p>TG Therapeutics expects BRIUMVI’s U.S. net product revenue to reach around $182 million in Q4 and $594 million for the full year of 2025. Global revenue for the year is estimated at $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.&nbsp;</p><p>Looking ahead, the company anticipates total global revenue between $875 million and $900 million for 2026, with U.S. BRIUMVI sales projected at $825 million to $850 million.</p><p>BRIUMVI is a glycoengineered monoclonal antibody that targets CD20-expressing B-cells, a proven approach for treating autoimmune diseases like relapsing multiple sclerosis (RMS). By removing specific sugar molecules, BRIUMVI enhances B-cell depletion at lower doses.</p><h2 class="st-heading-2">Upcoming Clinical Milestones</h2><p>The company also teased three major milestones for 2026.&nbsp;TG Therapeutics plans to release pivotal topline data for the ENHANCE trial, which evaluates Day 1 and Day 15 intravenous doses of BRIUMVI, by mid-2026. Preliminary Phase 1 data for azer-cel in Progressive multiple sclerosis (MS) will be shared in the latter half of the year.&nbsp;</p><p>Pivotal topline results for subcutaneous BRIUMVI are expected by year-end 2026 or early 2027.&nbsp;</p><p>TGTX stock has declined by over 6% in the last 12 months.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Biology lab technician removes a freeze-dried sample from a container in a laboratory.

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

December Jobs Data Put Focus on These Sector ETFs & Stocks

December jobs data highlight sector shifts as healthcare and restaurants add jobs, while retail lags. ETFs XLV, EATZ in focus.

<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul><p>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;</p><p>The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</p><h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2><p>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;</p><p>Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;</p><blockquote><p>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”</p><p>-Scott Hutton, CEO, Biodesix</p></blockquote><p>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2><p>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;</p><p>“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;</p><p>Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;</p><p>BDSX stock declined by over 77% in the last 12 months.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond

After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.

<ul class="summary-bullets"><li>Booth said timing drove sharply different investor outcomes in Ventyx.</li><li>Clear Street said Lilly was a logical buyer and cut Ventyx to ‘Hold’.</li><li>LifeSci Capital said the stock reset to ‘Market Perform’ after the deal.</li></ul><p>Ventyx’s path through public markets culminated in a $1.2 billion buyout by&nbsp;Eli Lilly, highlighting how timing drove investor outcomes, ranging from deep drawdowns to more than 2,000% upside.</p><p>That contrast was captured by Atlas Venture partner Bruce Booth,&nbsp;an early-stage biotech venture capitalist who&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/LifeSciVC/status/2009081510192914652">said on X</a>&nbsp;that the stock’s history has become a case study in how biotech returns can be dictated less by belief and more by when investors&nbsp;choose to step in.</p><h2 class="st-heading-2"><strong>Bottom Buyers Reaped The Gains</strong></h2><p>Booth said investors who bought Ventyx shares near the lows in early 2025 would have seen gains of more than 2,000% by the time the company agreed to be acquired. He added that investors who bought at the IPO ultimately got most of their money back, which he described as a win, given that the stock had been more than 90% underwater a year earlier.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260108_095534478_png_dfe989a876.webp" alt="koyfin_20260108_095534478.png" width="2400" height="1240"></figure><h2 class="st-heading-2"><strong>From Early Optimism To Strategic Reset</strong></h2><p>When Ventyx went public, its main drug program targeted TYK2, a protein involved in immune system signaling that is linked to autoimmune and inflammatory diseases. Over time, the company pivoted toward the NLRP3 inflammasome, reshaping its pipeline to focus on inflammatory, cardiometabolic, and neurodegenerative diseases.</p><p>That strategic reset proved critical. Lilly said the acquisition&nbsp;strengthened its position in cardiometabolic health, immunology, and neuroscience, while filling a gap in NLRP3 assets that could pair with its existing therapies.</p><p>Clear Street, which downgraded Ventyx to ‘Hold’ from ‘Buy’ following the deal, described Lilly as a “logical” buyer, noting that Ventyx’s inflammasome-focused portfolio complements Lilly’s franchises and addresses an area where Lilly previously lacked assets.&nbsp;</p><h2 class="st-heading-2"><strong>Clinical Data Sustained Interest Through&nbsp;</strong></h2><p>Despite extreme share price swings, Ventyx continued to generate clinical updates that kept its science in focus. In June, the company reported positive Phase 2a results for VTX3232 in early Parkinson’s disease. The study showed that the drug was safe and well-tolerated, reached the brain as intended, and reduced key inflammation-related biomarkers, indicating that it engaged its intended target.</p><p>VTX3232 targets NLRP3, a protein involved in driving inflammation in neurodegenerative diseases. In January 2025, H.C. Wainwright described Ventyx’s Phase 2 pipeline as high risk/high reward, citing both the potential of this inflammation-focused approach and the long history of difficulty in developing effective treatments for neurodegenerative disorders.</p><h2 class="st-heading-2"><strong>Wall Street Reframes After The Buyout</strong></h2><p>With the acquisition agreement in place, analysts moved to align ratings with the deal terms. LifeSci Capital downgraded Ventyx to ‘Market Perform’ from ‘Outperform’, setting a $14 price target after the company agreed to be acquired. Clear Street made a similar move, cutting the stock to ‘Hold’ from ‘Buy’ while raising its target from $11 to $14.</p><p>By contrast, UBS initiated coverage with a ‘Buy’ rating on Tuesday, citing improving biotech fundamentals, a recovering risk appetite, and Ventyx’s pipeline as among several small- and mid-cap biotech stories positioned for stronger performance in 2026.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Ventyx was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/vtyx_ss_png_0e1eef59df.webp" alt="vtyx ss.png" width="969" height="141"><figcaption>VTYX sentiment and message volume as of January 7| Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/VTYX">Ventyx’s stock</a> has surged 467% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Ventyx’s stock (VTYX) has surged 467% over the past 12 months. (Representative Image: Getty Images)

Ventyx’s $1.2B Buyout By Eli Lilly Proves Timing Often Beats Conviction In Biotech Investing — A VC Explains

Bottom buyers saw over 2,000% gains, while IPO investors merely broke even after a 90% drawdown, according to Atlas Venture’s Bruce Booth.

Bank of America shares S&P 500 warning for 2026

The stock market's under duress, but Wall Street's biggest banks feel it's still pretty expensive. Bank of America warns that theS&P 500 is priced for perfection as we progress deeper into 2026...

SSgA Active Trust - State Street Health Care Select Sector SPDR ETF

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$155.40
Prev Close	$155.74
Open	$154.00
Dividend Yield	N/A
50-Day Moving Average	$154.37
Beta	N/A
Avg. Volume	10.24M
PE Ratio	N/A

52-Week High	$160.59
52-Week Low	$127.35
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLV News

XLVHealth Care Select Sector SPDR Fund